Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2008-10-01 (17 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: STRASBOURG (67100), Bas-Rhin
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE LIZE : revenue, balance sheet and financial ratios
SELAS PHARMACIE LIZE is a French company
founded 17 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in STRASBOURG (67100),
this company of category PME
shows in 2023 a net income positive of 149 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE LIZE (SIREN 507696870)
Indicator
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
148 636 €
164 622 €
164 622 €
50 969 €
407 307 €
71 387 €
70 258 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2023, SELAS PHARMACIE LIZE generates positive net income of 149 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2023: 70 k€ -> 149 k€.
Net income (2023)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
148 636 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 158%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 29%. The balance between equity and debt is satisfactory.
Debt ratio (2023)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
158.296%
Financial autonomy (2023)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
29.232%
Asset age ratio (2023)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
Debt ratio
4204.196
855.048
129.134
390.002
262.51
262.51
158.296
Financial autonomy
1.795
8.069
37.869
15.312
21.701
21.701
29.232
Repayment capacity
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
158.32023
2021
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.24
Average
In 2023, the debt ratio of SELAS PHARMACIE LIZE (158.30) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
29.23%2023
2021
2022
2023
Q1: 28.72%
Med: 48.51%
Q3: 68.17%
Average
In 2023, the financial autonomy of SELAS PHARMACIE LIZE (29.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 171.94. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2023)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
Liquidity ratio
169.046
162.716
361.884
164.435
190.029
189.783
171.941
Interest coverage
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
171.942023
2021
2022
2023
Q1: 135.25
Med: 189.78
Q3: 270.35
Average-8 pts over 3 years
In 2023, the liquidity ratio of SELAS PHARMACIE LIZE (171.94) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of SELAS PHARMACIE LIZE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 220 transactions of similar company sales
in 2023,
the value of SELAS PHARMACIE LIZE is estimated at
1 753 826 €
(range 1 066 586€ - 2 465 487€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2023
220 transactions
1066k€1753k€2465k€
1 753 826 €Range: 1 066 586€ - 2 465 487€
NAF 5 année 2023
Valuation method used
Net Income Multiple
148 636 €
×
11.8x
=1 753 827 €
Range: 1 066 586€ - 2 465 487€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE LIZE with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE LIZE
What is the revenue of SELAS PHARMACIE LIZE ?
The revenue of SELAS PHARMACIE LIZE is not publicly disclosed (confidential accounts filed with INPI).
Is SELAS PHARMACIE LIZE profitable?
Yes, SELAS PHARMACIE LIZE generated a net profit of 149 k€ in 2023.
Where is the headquarters of SELAS PHARMACIE LIZE ?
The headquarters of SELAS PHARMACIE LIZE is located in STRASBOURG (67100), in the department Bas-Rhin.
Where to find the tax return of SELAS PHARMACIE LIZE ?
The tax return of SELAS PHARMACIE LIZE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE LIZE operate?
SELAS PHARMACIE LIZE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart